A new meta-analysis suggests that muscle loss, known as sarcopenia, may be common among Indian adults living with type 2 diabetes. However, the researchers stress that their estimates are very uncertain and not yet strong enough to recommend routine screening. This matters because people with type 2 diabetes often face muscle weakness and frailty as they age, which can affect daily life and independence.
The study pooled data from multiple studies that together included 1,359 Indian adults aged 18 and older with type 2 diabetes. The researchers used the Asian Working Group for Sarcopenia (AWGS) criteria to identify sarcopenia. They looked at how common different forms of sarcopenia were, including confirmed sarcopenia, severe sarcopenia, sarcopenic obesity (muscle loss with excess body fat), and possible sarcopenia. They also examined factors linked to sarcopenia, such as high blood pressure and longer diabetes duration.
The main finding was that about 27.4% of these adults had confirmed sarcopenia. In plain terms, roughly 1 in 4 people in the pooled studies had this condition. The prevalence varied a lot depending on how muscle mass was measured: about 20.2% when using dual-energy X-ray absorptiometry (DXA) and 31.7% when using bioelectrical impedance analysis (BIA). Severe sarcopenia was found in 11.0% of cases, sarcopenic obesity in 25.2%, and possible sarcopenia in 65.6%. The researchers also found that high blood pressure and having diabetes for 10 years or more were linked to a higher chance of sarcopenia. These are associations, not proof of cause and effect.
No safety concerns or side effects were reported because this was a meta-analysis of existing studies, not a trial of a treatment. The main issue is the quality of the evidence. The researchers rated the certainty of all prevalence estimates as very low. There was also high heterogeneity, meaning the individual studies gave widely different results. For confirmed sarcopenia, the statistical inconsistency was 91.7%, and for possible sarcopenia it was 98.6%. The prediction interval for confirmed sarcopenia ranged from 6.9% to 65.6%, showing just how imprecise the estimate is. Because the included studies were cross-sectional, they can only show links at one point in time, not cause and effect.
For patients right now, this study does not change screening guidelines. It does highlight that muscle health may be an important issue for people with type 2 diabetes in India, but the exact numbers are still unclear. Anyone concerned about muscle weakness or frailty should talk to their doctor. More research with better methods is needed before routine screening can be recommended.
